Journal article
Needle before Scalpel: Considering the Role of Intratumoral Therapy in Melanoma
Dermatologic therapy, Vol.2024(1), 8820105
07/27/2024
DOI: 10.1155/2024/8820105
Appears in UI Libraries Support Open Access
Abstract
Advanced melanoma and nonmelanoma skin cancer or cutaneous metastases not amenable to surgery often require alternate therapy. Although surgery is first‐line treatment for early‐stage melanoma, it can be challenging with multifocal disease, sites with high morbidity, large lesions such as lentigo maligna on the head and neck, and patients with comorbidities that add surgical risk. Intratumoral therapy is a safe method of treating advanced melanoma which avoids the toxicities of systemic therapies. Our review examined the overall response rates and adverse effects of the following experimental and standard intralesional agents: ipilimumab, rose bengal (PV‐10), cathelicidin LL37, SD‐101, coxsackie A21 V937, and talimogene laherparepvec. Injection of oncolytic virus, immune‐modulating drugs, cytotoxic agents, or studied combinations was well‐tolerated and effective alternative treatments for advanced melanoma and cutaneous metastases. Response to treatment was observed in both injected and noninjected lesions demonstrating systemic antitumor effects of these intralesional therapies. Further utility of intralesional agents can be explored as neoadjuvant treatment of large lentigo maligna lesions or those in cosmetically sensitive areas. Intralesional therapy should be developed further for morbidity reduction in challenging melanoma cases.
Details
- Title: Subtitle
- Needle before Scalpel: Considering the Role of Intratumoral Therapy in Melanoma
- Creators
- Theodore Henry Katz - University of Iowa, Orthopedics and RehabilitationAsad Javed - University of Iowa, Hematology, Oncology, and Blood & Marrow TransplantationJennifer G. Powers - University of Iowa, Dermatology
- Resource Type
- Journal article
- Publication Details
- Dermatologic therapy, Vol.2024(1), 8820105
- Publisher
- Wiley
- DOI
- 10.1155/2024/8820105
- ISSN
- 1396-0296
- eISSN
- 1529-8019
- Grant note
Open access funding was enabled and organized by BTAA 2023.DAS:Due to the nature of this review study, all of the objective information can be readily found in the references.
- Language
- English
- Date published
- 07/27/2024
- Academic Unit
- Orthopedics and Rehabilitation; Hematology, Oncology, and Blood & Marrow Transplantation; Dermatology; Internal Medicine
- Record Identifier
- 9984690058202771
Metrics
4 Record Views